Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(22):1680-1681; doi:10.1093/jnci/93.22.1680
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Dunn, F. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunn, F. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 22, 1680-1681, November 21, 2001
© 2001 Oxford University Press

NEWS

Anthrax as a Cancer Drug?

F. B. Dunn

Once the home of the U.S. bioweapons program, Fort Detrick, Md., site of a condemned seven-story tower where tons of deadly anthrax spores once lay, now serves as a cynosure of anthrax defense research.


Figure Removed (Available Only in the Full Text)
View larger version (181K):
[in this window]
[in a new window]
  		Fort Detrick in Frederick, Md., is the home of the National Cancer Institute’s Frederick Cancer Research and Development Center and of the U.S. Army Medical Research Institute of Infectious Diseases.

 
In 1969, President Nixon signed an order ending the U.S. bioweapons program. Now, 3 decades later, scientists at Fort Detrick are transforming anthrax’s deadly toxins into 21st century cancer fighters. A mix of basic science and serendipity and a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?